Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
NCT ID: NCT04147975
Last Updated: 2019-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
225 participants
OBSERVATIONAL
2019-10-01
2020-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala
NCT05314816
Rapid Detection of Group B Strep- 35-37 Week Study
NCT00331019
Carriage of Beta Haemolytic Streptococci During Pregnancy
NCT05365711
Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections
NCT00709358
Rapid Strep Test Results
NCT04256694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients Suspected of Bloodstream Infection
No intervention(s) to be administered.
RaPID/BSI Test
RaPID/BSI Test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RaPID/BSI Test
RaPID/BSI Test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HelixBind, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HelixBind Inc.
Marlborough, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alon Singer, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20031
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.